Combat injuries often lead to bloodstream infections that can progress to sepsis, a life-threatening condition marked by an early surge of inflammation followed by dangerous immune suppression. In remote or delayed-care environments, current treatments struggle to restore this balance, leaving service members vulnerable to secondary infections and poor outcomes. The project develops a new class of lipid nanoparticle (LNP) therapeutics designed to target immune cells, especially macrophages, to control inflammation and rebuild an effective immune response. Researchers will construct and test a large library of LNP formulations using automated, high-throughput methods. These particles will carry clinically approved and experimental bioactive lipids intended to dampen harmful inflammation and prevent immune exhaustion. Screening will rely on reporter macrophage assays that track activation of key inflammatory pathways and cytokine profiles, followed by validation in human macrophages and rodent models of sepsis. The work seeks practical treatments that can be deployed in austere settings, improving survival and recovery for injured personnel when conventional care is limited.